<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568877</url>
  </required_header>
  <id_info>
    <org_study_id>UniversidadMHE_Met AMPK</org_study_id>
    <nct_id>NCT03568877</nct_id>
  </id_info>
  <brief_title>Effect of Metabolaid® on AMPK Activation for Weight Loss</brief_title>
  <official_title>Anti-obesity Effects of Metabolaid® With AMPK-activating Capacity in Overweight Subjects: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Miguel Hernandez de Elche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monteloeder SL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Miguel Hernandez de Elche</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to establish a formulation, containing both Hibiscus
      sabdariffa L. (HS) and Lippia citriodora L. (LC) extracts (Metabolaid®) that had significant
      capacity to activate the AMPK-enzyme and to reduce triglyceride accumulation in the
      hypertrophied adipocyte model. Then, we assessed the efficacy of this combination in
      light-to-moderate-overweight subjects under risk of developing metabolic syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMP-activated protein kinase (AMPK) has been postulated as a molecular target in the
      amelioration of obesity-related diseases, where most therapeutic approaches have failed.
      Plant-polyphenols have shown the capacity to ameliorate obesity-induced metabolic
      disturbances. A combination of polyphenols (LC-HS) derived from Hibiscus sabdariffa L. (HS)
      and Lippia citriodora L. (LC) (lemon verbena) (Metabolaid®) was assessed for triglyceride
      accumulation and AMPK activation in the hypertrophied adipocyte model 3T3-L1. A dietary
      supplement containing 500 mg of LC-HS was evaluated in a double blind, placebo-controlled and
      randomized trial in 56 overweight subjects for two months. Anthropometric and circulating
      biochemical parameters were determined.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in body Weight, using a weight scale</measure>
    <time_frame>At the beginning, four weeks and end of the intervention, total eight weeks.</time_frame>
    <description>In Kg</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Height, using measuring tape</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>In cm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI, calculated based on Weight and Height</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference, using a measuring tape</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>in kg/m^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Blood Sampling in Fasting conditions, in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tryglicerides</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Blood Sampling in Fasting conditions, in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL Cholesterol</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Blood Sampling in Fasting conditions, in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL Cholesterol</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Blood Sampling in Fasting conditions, in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Blood Sampling in Fasting conditions, in mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Single Blood Pressure measurements, using the Omron M6 Comfort device</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>At the beginning, four weeks and eight weeks</time_frame>
    <description>Single Blood Pressure measurements, using the Omron M6 Comfort device</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 capsules per day, each with 400 mg Cellulose microcrystalline, for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dietetic Supplement Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 Capsules per day of Metabolaid® (each capsule contains 250 mg Metabolaid®, 150 mg cellulose microcrystalline), for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Metabolaid®</intervention_name>
    <description>500 mg per day, in fasting conditions.</description>
    <arm_group_label>Dietetic Supplement Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg per day, in fasting conditions.</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with a body mass index (BMI) from 24 to 34 kg/m2

        Exclusion Criteria:

          -  total cholesterol lower than 200 mg/dL.

          -  use of prescription medication for cholesterol or hypertension.

          -  presence of any obesity-related pathology.

          -  hormone replacement therapy.

          -  consumption of antioxidant supplements/drugs.

          -  alcohol addiction.

          -  women who were pregnant or lactating.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>36 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Universidad Miguel Hernandez de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>May 30, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>June 25, 2018</last_update_submitted>
  <last_update_submitted_qc>June 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Miguel Hernandez de Elche</investigator_affiliation>
    <investigator_full_name>María Herranz-Lopez</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

